Parkinson's Breakthrough? New Drug Shows Promise in Halting Disease

ATLANTA, GA – February 20, 2026 – In what could represent a pivotal moment in the fight against Parkinson's disease, ABLi Therapeutics has announced groundbreaking results from a Phase 2 trial of its investigational drug, risvodetinib. Published in the prestigious journal Nature Aging, the study reveals that the once-daily oral medication is not only safe but is also the first therapy to demonstrate a reduction in the toxic protein clumps that are a central cause of the neurodegenerative disorder.

For millions living with Parkinson's, current treatments only manage symptoms, leaving the disease's relentless progression unchecked. The new data suggests that risvodetinib may be the first true disease-modifying therapy, offering the potential to slow or even halt the devastating course of the illness.

“Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than a million people in the U.S. alone. To date, there are no approved therapies to slow or halt disease progression. Inhibition of the c-Abl kinases by risvodetinib is becoming recognized as the first therapeutic approach that may be able to both block pathways of cell death and suppress neuroinflammation, the two hallmarks of neurodegeneration in PD,” noted Dr. Milton Werner Chairman and Chief Executive of ABLi Therapeutics. “The outstanding safety and tolerability of risvodetinib over 12-weeks and the reduction in the alpha-synuclein pathology linked to the cause of disease provide additional confidence that long-term efficacy studies could result in the first disease-modifying therapeutic for PD.”

Targeting the Root Cause of Neurodegeneration

Unlike existing Parkinson's medications that primarily focus on replenishing dopamine, a neurotransmitter lost as the disease progresses, risvodetinib takes a fundamentally different approach. It is a potent, selective small-molecule inhibitor designed to block the activity of c-Abl kinases.

Scientific research has increasingly implicated overactive c-Abl kinases in the pathology of Parkinson's. This enzyme's hyperactivity is believed to trigger a toxic cascade, promoting the misfolding and aggregation of a protein called alpha-synuclein. These aggregates form Lewy bodies, the sticky, damaging clumps found in the brain cells of people with Parkinson's, which ultimately lead to neuronal death and the onset of motor and non-motor symptoms.

By inhibiting c-Abl, risvodetinib is designed to intervene directly in this process. The therapeutic goal is twofold: to prevent the formation of new alpha-synuclein aggregates and to help the body's natural clearance systems remove existing ones. This dual action of blocking cell death pathways and quelling neuroinflammation represents a significant departure from the symptomatic treatments that have defined Parkinson's care for decades.

Decoding the '201 Trial' Results

The findings published in Nature Aging stem from the '201 Trial' (NCT05424276), a 12-week, randomized, double-blind, placebo-controlled study involving 126 patients with untreated, early-stage Parkinson's disease. The trial's primary goal was to establish the safety and tolerability of risvodetinib at three different daily doses (50 mg, 100 mg, and 200 mg).

The drug successfully met this primary endpoint, demonstrating a favorable safety profile with adverse events that were mild-to-moderate and occurred with similar frequency to the placebo group. Critically, the study saw a 95% completion rate and 99% dosing compliance, indicating that the drug was well-tolerated by participants—a crucial factor for any potential long-term therapy.

While not powered to prove efficacy, the trial's secondary endpoints provided compelling hints of clinical benefit. Of 15 different outcome measures assessing motor function, daily living activities, and non-motor symptoms, 13 showed a numerical trend favoring risvodetinib over placebo. Notably, improvements in the MDS-UPDRS Part II scale, which measures the impact of symptoms on daily life, reached nominal statistical significance at the 100 mg dose. Similarly, the Schwab & England Activities of Daily Living (SEADL) scale showed a statistically significant benefit at the 50 mg dose, suggesting a tangible positive impact on patient quality of life even over the short 12-week period.

The Alpha-Synuclein Breakthrough

The most significant finding, however, came from an exploratory analysis of skin biopsies. For the first time, a therapeutic has shown a dose-dependent reduction in the levels of phosphorylated alpha-synuclein in nerve fibers within the skin. This biomarker is considered a direct proxy for the disease pathology occurring in the brain.

"We are very encouraged by the preliminary data generated using our Syn-One Biomarker Services in ABLi’s 201 Trial for risvodentinib,” said Christopher Gibbons, MD, Chief Scientific Officer of CND Life Sciences. “Multiple natural history studies have shown that phosphorylated alpha-synuclein increases over time, but in the ABLi 201, study there was a dose-dependent decrease in synuclein over 12 weeks.”

This result is a potential game-changer. The ability to directly measure and reduce the core pathology of Parkinson's has been a long-sought goal in neurodegenerative research. It provides the first biological evidence that a drug can modify the underlying disease process. The finding has been met with enthusiasm from regulatory bodies, with the U.S. Food and Drug Administration (FDA) encouraging ABLi to continue using this skin biopsy measure in future, larger trials as a potential marker of treatment success.

The Path Forward: From Trial to Treatment

Buoyed by these promising Phase 2 results, ABLi Therapeutics is already charting a clear course toward bringing risvodetinib to patients. The company has held an End-of-Phase-2 meeting with the FDA and is planning a large-scale Phase 3 registrational study, dubbed the "C-Abl Modification of Parkinson's disease (CAMPD)" trial. This pivotal study will enroll approximately 450 untreated patients and will be designed to definitively prove the drug's ability to slow or halt disease progression over a longer period.

In the interim, participants from the '201 Trial' will be offered the chance to enroll in a 12-month open-label extension study, allowing for continued assessment of the drug's long-term safety and effects on functional decline.

Furthermore, ABLi is expanding its investigation of risvodetinib to other related neurodegenerative conditions. A Phase 2/3 trial is planned for Multiple System Atrophy (MSA), another devastating synucleinopathy that shares pathological features with Parkinson's but progresses much more rapidly. This reflects a broader strategy to leverage the drug's unique mechanism across a range of diseases driven by c-Abl dysfunction and alpha-synuclein aggregation. The company's intellectual property for risvodetinib, protected beyond 2036, provides a long runway for this ambitious development program, offering a sustained glimmer of hope for a future where neurodegenerative diseases are not just managed, but meaningfully treated.